https://www.vertexventureshc.com/2026-04-21T02:18:18.507Zhttps://www.vertexventureshc.com/news/2026-04-21T02:07:46.233Zhttps://www.vertexventureshc.com/legal/2024-08-22T02:30:08.726Zhttps://www.vertexventureshc.com/contact/2026-04-20T10:20:17.068Zhttps://www.vertexventureshc.com/news/bicycle-therapeutics-establishes-multiple-strategic-partnerships-to-create-end-to-end-supply-chain-to-support-its-wholly-owned-radiopharmaceutical-pipeline/2026-05-18T02:03:57.194Zhttps://www.vertexventureshc.com/news/6fd914c0-1180-4553-b819-a01b86fd3c28/2026-04-21T08:14:08.955Zhttps://www.vertexventureshc.com/news/allay-therapeutics-announces-57-5m-series-d-financing-and-venture-debt-line-to-advance-atx101-and-its-ultra-sustained-pain-platform-for-post-surgical-pain-management/2025-07-30T07:38:34.881Zhttps://www.vertexventureshc.com/news/obsidian-therapeutics-announces-positive-clinical-data-from-obx-115-in-patients-with-advanced-melanoma-in-ongoing-multicenter-study-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting/2025-07-30T06:14:07.837Zhttps://www.vertexventureshc.com/news/spyglass-pharma-raises-75-million-series-d-funding-to-advance-its-long-term-drug-delivery-platform-for-glaucoma-patients/2025-07-30T06:23:27.831Zhttps://www.vertexventureshc.com/news/first-patients-treated-in-a-new-randomized-controlled-trial-evaluating-the-misha-knee-system-vs-non-surgical-treatment-for-knee-osteoarthritis/2025-06-18T09:56:38.341Zhttps://www.vertexventureshc.com/news/spyglass-pharma-presents-18-month-data-demonstrating-compelling-visual-acuity-results-with-their-iol-mounted-innovative-drug-delivery-platform/2026-04-22T02:49:31.244Zhttps://www.vertexventureshc.com/news/neuspera-medical-announces-landmark-six-month-clinical-trial-results-for-the-first-battery-free-percutaneous-sacral-neuromodulation-psnm-system-for-urgency-urinary-incontinence-management/2026-04-22T02:47:38.859Zhttps://www.vertexventureshc.com/news/elevatebio-announces-compelling-preclinical-data-demonstrating-the-potential-of-leti-101-as-a-treatment-for-huntington-s-disease/2026-04-22T02:52:46.209Zhttps://www.vertexventureshc.com/news/allay-therapeutics-announces-first-patients-dosed-in-pivotal-phase-2b-registration-trial-of-atx101-for-post-surgical-pain-management-after-knee-replacement-surgery/2025-06-12T06:48:47.623Zhttps://www.vertexventureshc.com/news/vertex-ventures-hc-announces-christine-brennan-ph-d-appointed-to-bio-board-of-directors/2025-02-04T14:48:18.272Zhttps://www.vertexventureshc.com/news/sonotheratm-expands-leadership-team-appointing-carolyne-zimmermann-as-chief-business-officer/2023-11-19T14:06:13.098Zhttps://www.vertexventureshc.com/news/vertex-ventures-hc-announces-200-million-fund-iii-to-drive-innovation-in-healthcare/2024-02-06T12:11:52.324Zhttps://www.vertexventureshc.com/news/the-power-of-diversity-the-future-of-funding/2024-02-06T12:10:27.419Zhttps://www.vertexventureshc.com/news/sonotheratm-receives-exclusive-licensing-of-ge-healthcare-s-optison-and-sonazoid-microbubble-products-for-use-with-its-ultrasound-guided-gene-therapy-platform/2024-02-06T12:12:49.152Zhttps://www.vertexventureshc.com/news/palleon-co-founder-dr-carolyn-bertozzi-awarded-nobel-prize-in-chemistry-for-pioneering-methods-of-studying-glycobiology/2023-01-05T11:32:46.127Zhttps://www.vertexventureshc.com/news/legacies-60-biopharma-pioneers-over-60-who-helped-birth-a-tech-revolution-in-the-making/2024-02-06T11:26:02.848Zhttps://www.vertexventureshc.com/news/taking-biopharmaceutical-visterra-from-investment-to-multi-million-dollar-m-a/2022-10-04T06:16:33.190Zhttps://www.vertexventureshc.com/news/ivantis-announces-results-of-landmark-prospective-randomized-comparative-migs-clinical-trial/2022-10-04T06:19:33.681Zhttps://www.vertexventureshc.com/news/ivantis-hits-2-major-milestones-for-its-minimally-invasive-glaucoma-surgery/2022-10-04T06:19:20.004Zhttps://www.vertexventureshc.com/news/palleon-scientific-co-founder-dr-carolyn-bertozzi-describes-how-sugars-interact-with-the-immune-system-at-tedxstanford/2022-10-13T01:01:24.263Z